Saad Z. Usmani, MD, Atrium Health

Dr. Usmani on the Rapidly Evolving Landscape in Multiple Myeloma

August 17th 2022

Saad Z. Usmani, MD, MBA, FACP, discusses the rapidly evolving treatment landscape in multiple myeloma.

Dr. Usmani on Emerging Treatment Strategies in Late Relapsed Multiple Myeloma

February 2nd 2022

Saad Z. Usmani, MD, MBA, FACP, discusses emerging treatment strategies in late relapsed multiple myeloma.

ASH Takeaways and Future Directions for Multiple Myeloma

March 11th 2021

Paul G. Richardson, MD; Nina Shah, MD; David Siegel, MD, PhD; and Saad Z. Usmani, MD, provide closing thoughts and key takeaways on multiple myeloma from the 2020 ASH Virtual Meeting and future directions for disease management. 

Sequencing BCMA-Targeted Agents in RRMM

March 11th 2021

Insights on approaching the sequencing of BCMA-targeted agents and whether antigen loss is considered an issue in RRMM. 

Non-BCMA Specific Targets in RRMM

March 11th 2021

Examining non-BCMA BiTE (bispecific T-cell engager) approaches to therapy, such as talquetamab and BFCR4350A, for the treatment of RRMM. 

Dr. Usmani on the Potential Utility of Allogeneic CAR T-Cell Therapy in Multiple Myeloma

March 9th 2021

Saad Z. Usmani, MD, FACP, discusses the potential utility of allogeneic CAR T-cell therapy in multiple myeloma.

Investigational BCMA Targets in RRMM

March 4th 2021

Exploring other investigational BCMA-targeting agents such as teclistamab, AMG 701, and TNB-383B for the management of RRMM. 

Targeting BCMA and CAR T Therapy in RRMM

March 4th 2021

Nina Shah, MD, leads the conversation of using BCMA-targeted antibody-drug conjugate belantamab mafodotin, and the emerging role of CAR T-cell therapy when treating RRMM. 

Emerging Novel Agents in RRMM

February 25th 2021

Paul G. Richardson, MD, reviews early data presented at ASH 2020 on the use of CELMoDs as well as melflufen for the management of RRMM. 

Using PI-based Combinations in RRMM

February 25th 2021

Saad Z. Usmani, MD, leads the discussion on new and updated data for novel PI-based combinations in RRMM as seen in the CANDOR, IKEMA, and BOSTON trials.

Role of IMiD-based Strategies for RRMM

February 18th 2021

Approaching Treatment of RRMM

February 18th 2021

Future of MRD Assessment in NDMM

February 10th 2021

ASH Updates on Transplant in NDMM

February 10th 2021

Individualized Induction Therapy for NDMM

February 3rd 2021

Approaching Early Treatment of High-Risk SMM

February 3rd 2021

Role of Therapeutic Intervention in SMM

January 27th 2021

Overview of Smoldering Multiple Myeloma

January 27th 2021